AllSquare Wealth Management LLC Grows Stake in Zoetis Inc. (NYSE:ZTS)

AllSquare Wealth Management LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 20.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 948 shares of the company’s stock after purchasing an additional 158 shares during the period. AllSquare Wealth Management LLC’s holdings in Zoetis were worth $154,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Holderness Investments Co. grew its stake in Zoetis by 25.6% during the fourth quarter. Holderness Investments Co. now owns 4,663 shares of the company’s stock valued at $760,000 after acquiring an additional 950 shares in the last quarter. HUB Investment Partners LLC grew its position in shares of Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares in the last quarter. Whittier Trust Co. grew its position in shares of Zoetis by 9.5% during the fourth quarter. Whittier Trust Co. now owns 12,167 shares of the company’s stock valued at $1,982,000 after purchasing an additional 1,055 shares in the last quarter. Blueshift Asset Management LLC bought a new stake in shares of Zoetis in the fourth quarter worth about $280,000. Finally, Magnetar Financial LLC lifted its position in shares of Zoetis by 38.0% in the fourth quarter. Magnetar Financial LLC now owns 34,408 shares of the company’s stock worth $5,606,000 after buying an additional 9,471 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ZTS shares. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Stock Performance

Shares of Zoetis stock opened at $163.15 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a market capitalization of $73.06 billion, a PE ratio of 29.83, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The stock’s fifty day moving average is $166.77 and its two-hundred day moving average is $175.67. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock worth $312,254 over the last three months. 0.16% of the stock is owned by corporate insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.